Results from the University of the Witwatersrand (Wits) Novavax coronavirus (Covid-19) vaccine trial shows 51% efficacy against the B.1.351 variant in a South African study with HIV negative participants. A group in the trial, which included people who are HIV positive, showed 43% efficacy.
from Engineering News | Home https://ift.tt/3esnATL
